There are currently 224 clinical trials in Newport Beach, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Hoag Memorial Hospital Presbyterian, USC Norris Oncology/Hematology-Newport Beach, Eye Research Foundation and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Atrial Fibrillation Ablation Registry
Recruiting
The Atrial Fibrillation Ablation Registry (AFib Ablation Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous catheter ablation procedures to treat atrial fibrillation (AF).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: Hoah Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Atrial Fibrillation
STS & ACC Foundation's Transcutaneous Valve Therapy (TVT) Registry Foundation's Transcutaneous Valve Therapy (TVT) Registry
Recruiting
The TVT Registry was designed to support a national surveillance system to assess the characteristics, treatments, and outcomes of patients receiving transcutaneous valve therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: Hoah Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Transcutaneous Valve Therapies
U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
Recruiting
This is an observational, biospecimen collection protocol to develop a bank of pancreatic cancer tissue and normal tissue.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Pancreatic Cancer
AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
Recruiting
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Eye Research Foundation, Newport Beach, California
Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
A Study of ZN-c3 in Participants With Solid Tumors
Recruiting
This is a Phase 1 open-label, multicenter study of ZN-c3 monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Site 0167, Newport Beach, California
Conditions: Solid Tumor
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Eye Research Foundation Inc., Newport Beach, California
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
Recruiting
This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/20/2021
Locations: Steve Yoelin MD, Newport Beach, California
Conditions: Glabellar Frown Lines
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Newport Beach, California
Conditions: Ulcerative Colitis